|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||53.06 / 66.80|
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who...
Merck, known as MSD outside the United States and Canada, announced today a $300,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company's established and investigational...
GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN ® Donation Program (MDP) congratulate President Faure Gnassingbé, the government and the people of Togo for becoming the first country in Africa recognized by...
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
The most recent short interest data has been released for the 03/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr.
'These companies are all assessing the Trump effect,' Cramer said.
Incyte has been doing great, locking in deals with Bristol-Myers and Merck. It's worth a lot more in a takeover situation, Cramer said.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2017 Partner of the Year - Sustained Excellence Award from the U.
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company's chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on...
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
It's pretty normal to have profit-taking after such a strong first quarter.
The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.
We know that we are in the era when index managers are ascendant.
Johnson & Johnson is the better investment today versus Merck.
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of...
Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.
Wall Street could be in for a rocky week in the wake of the Republicans' failure to repeal and replace Obamacare as promised.
The vote on repealing and replacing Obamacare has been pulled from the House floor.
Merck is struggling to attract buyers as it tests a key support area.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.